Is compounded tirzepatide legal?
Only in narrow cases. Since the FDA confirmed in December 2024 that the tirzepatide shortage was over, pharmacies may not regularly make copies of Zepbound or Mounjaro (tirzepatide) unless a prescriber documents a significant difference needed by a specific patient. Compounded tirzepatide is not FDA-approved, and the FDA is acting against mass-marketed versions.
What changed when the tirzepatide shortage ended?
Pharmacies were allowed to make copies while tirzepatide was in shortage. The FDA first declared the shortage resolved on October 2, 2024, confirmed that on December 19, 2024 after a second review, then ended that allowance.1
Its grace period ended on February 18, 2025 for state-licensed compounding pharmacies (called 503A pharmacies) and on March 19, 2025 for outsourcing facilities (503B).1
Now a 503A pharmacy may not compound, “regularly or in inordinate amounts,” drugs that are “essentially copies” of an approved product, meaning the same active ingredient in a similar strength. The exception is when a prescriber “determines and documents” a change that makes “a significant difference” for a named patient.1 The FDA has said it won’t act against a pharmacy that fills 4 or fewer such prescriptions in a month.1
What about large outsourcing facilities?
On April 30, 2026, the FDA proposed leaving tirzepatide, semaglutide and liraglutide off the list of ingredients that outsourcing facilities may compound from in bulk, saying there is no clinical need.4
“When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need,” the FDA Commissioner said.5 The FDA extended the comment period to July 30, 2026. We found no final decision as of October 12, 2026.4
What is the FDA doing about sellers?
On February 6, 2026, the FDA said it would restrict the ingredients for compounded GLP‑1s “being mass-marketed” and warned of seizures and injunctions.3
It also said companies can’t call compounded products “generic versions or the same as drugs approved by FDA” or “clinically proven”.3 Compounded drugs are not FDA-approved, so the FDA doesn’t review their safety, effectiveness or quality.2
By May 31, 2026, the FDA had “more than 730 reports” of adverse events associated with compounded tirzepatide.2 It also warns about tirzepatide sold “for research purposes” or “not for human consumption”, which it calls illegal.2 Its advice: get a prescription and use a state-licensed pharmacy.2 See also Is compounded semaglutide the same as Ozempic? and Guide 7.
Read the full picture
Related questions
Sources
- FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Content current as of Apr 1, 2026. fda.gov
- FDA. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Content current as of Oct 1, 2026 (adverse-event counts as of May 31, 2026). fda.gov
- FDA. FDA intends to take action against non-FDA-approved GLP-1 drugs. Press announcement, Feb 6, 2026. fda.gov
- FDA. “List of bulk drug substances for which there is a clinical need under section 503B of the Federal Food, Drug, and Cosmetic Act.” Federal Register notice, May 1, 2026 (91 FR 23431; proposes not to include semaglutide, tirzepatide and liraglutide), and extension of comment period to Jul 30, 2026, Jun 26, 2026 (91 FR 38719). federalregister.gov
- Epstein Becker Green. “FDA proposal would leave semaglutide, tirzepatide, and liraglutide off 503B bulks list.” Health Law Advisor, May 6, 2026 (FDA announcement of Apr 30, 2026, “no clinical need”, Commissioner’s quote). Secondary source. ebglaw.com
Last checked Oct 12, 2026 · Next review due Apr 12, 2027 · Report an error
How this answer was made. Written by the GLP Guidebook team from the sources above, all checked on Oct 12, 2026. This is a plain summary of FDA statements, not legal advice. We don’t name or link to any seller. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call 911. How we write